简单介绍黄志纾，1965年6月生，理学博士，教授，博士生导师。中山大学药学院药物化学研究所所长。现为全国化学生物学专业委员会委员，全国药物化学专业委员会委员，全国药学专业学位工作委员会委员，广东省药学会药物化学专业委员会主任委员。主要从事药物化学、化学生物学科领域的教学和科研工作。1999年获中山大学有机化学博士学位。1998-1999年应邀在香港科技大学化学系进行中药化学的合作研究工作。2001-2003年在美国得克萨斯大学奥斯汀分校药学院药物化学系（The Division of Medicinal Chemistry, the College of Pharmacy, the University of Texas at Austin）进行博士后研究工作。先后主持国家自然科学基金重点项目、重大研究计划项目、面上项目以及省部级科研项目多项。在国内外重要学术刊物，包括J. Am. Chem. Soc., Nucleic Acids Res., Cell Chem. Biol., J. Med. Chem., Brit. J. Pharmacol., Org. Lett., ACS Chem. Biol., Chem. Commun., Anal. Chem., Eur. J. Med. Chem., Oncogene等发表论文200余篇，通讯或第一论文110余篇。多项中国发明专利获得授权。现为Annual Reports in Medicinal Chemistry、《中国药物化学杂志》、《中国药学》英文版编委。曾担任《Current Topics in Medicinal Chemistry》特刊客座主编，参与编写《有机化学》、《生物化学》、《药物化学》、《Medicinal Chemistry of Nucleic Acids》等教材和专著。曾获广东省科学技术一等奖、广东省教学成果一等奖。曾入选教育部新世纪优秀人才、广东省特支计划领军人才和杰出人才支持计划。曾获“挑战杯”全国大学生课外学术科技作品竞赛“优秀指导教师”、“南越优秀教师”、广东省“三八红旗手”等荣誉称号。
社会/学术任职
Current Medicinal Chemistry编委（2016-2018）
Annual Reports in Medicinal Chemistry编委（2016-）
Current Topics in Medicinal Chemistry-Gust editor (2015, volume 15, number 19)
《中国药学》（英文版）第四届编委（2014-）
《中国药物化学杂志》第六、七届编委（2010-）
2014全国药学专业学位工作委员会委员（2014-）
全国药物化学专业委员会委员（2011-）
全国化学生物学专业委员会委员（2010-）
广东省药学会药物化学专业委员会主任委员（2015-）
在研科研项目
激活AMPK通路并促进脂肪细胞棕色化的抗肥胖症先导化合物发现及作用机制研究, 国家自然科学基金，负责，2017-2020。
1.1类抗肥胖及其并发症新药SYSU-3d的临床前研究，广州市科技计划项目-产学研协同创新重大专项民生科技专题，负责人，2017-2020。
端粒G-四链体结构调控端粒功能的分子机制及化学干预策略，广东省自然科学基金重大基础研究培育项目，负责人，2017-2021。
DNA同源重组修复关键蛋白BLM新型小分子抑制剂的发现及其抗癌作用新机制研究，国家自然科学基金，负责，2019-2022。
能量代谢调控新靶点、新机制发现与创新药物研究，国家自然科学基金重点项目，负责，2020-2024。
部分代表性论文（均为通讯作者）：
Bouchardatine analogue alleviates NAFLD/NASH in high fat fed mice via blunting ATP synthase activity, Brit. J. Pharmacol. 2019, 176, 2877-2893.
Discovery of Isaindigotone Derivatives as Novel Bloom’s Syndrome Protein (BLM) Helicase Inhibitors That Disrupt the BLM/DNA Interactions and Regulate the Homologous Recombination Repair, J. Med. Chem. 2019, 62, 3147–316
Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes, J. Med. Chem. 2019, 62, 2060–2070.
Identification of G-Quadruplex-Binding Protein from the Exploration of RGG Motif/G-Quadruplex Interactions, J. Am. Chem. Soc. 2018, 140, 17945–17955.
Discovery of novel schizocommunin derivatives as telomeric G-quadruplex ligands that trigger telomere dysfunction and the deoxyribonucleic acid (DNA) damage response, J. Med. Chem. 2018, 61, 3436–3453.
Design, synthesis, and evaluation of new selective NM23-H2 binders as c-MYC transcription inhibitors via disruption of the NM23-H2/G-quadruplex interaction, J. Med. Chem. 2017, 60, 6924–6941.
New disubstituted quindoline derivatives inhibiting Burkitt’s lymphoma cell proliferation by impeding c-MYC transcription, J. Med. Chem. 2017, 60, 5438–5454.
Natural alkaloid bouchardatine ameliorates metabolic disorders in high‐fat diet‐fed mice by stimulating the sirtuin 1/liver kinase B‐1/AMPK axis, Brit. J. Pharmacol. 2017, 174, 2457-2470.
Design, synthesis and evaluation of isaindigotone derivatives to downregulate c-myc transcription via disrupting the interaction of NM23-H2 with G-quadruplex, J. Med. Chem. 2017, 60, 1292-1308.
Specific targeting of telomeric multimeric G-quadruplexes by a new triaryl-substituted imidazole, Nucleic Acids Res. 2017, 45, 1606-1618.
Conformation selective antibody enables genome profiling and leads to discovery of parallel G-quadruplex in human telomeres. Cell Chem. Biol. 2016, 23, 1261-1270.
Visualization of?NRAS?RNA G-quadruplex structures in cells with an engineered fluorogenic hybridization probe. J. Am. Chem. Soc.?2016,?138?, 10382–10385.
Synthesis and mechanism studies of 1,3-benzoazolyl substituted pyrrolo[2,3b]pyrazine derivatives as nonintercalative topoisomerase II catalytic inhibitors, J. Med. Chem. 2016, 59, 238-252. ?
Synthesis and biological evaluation of novel bouchardatine derivatives as potential adipogenesis/lipogenesis inhibitors for antiobesity treatment, J. Med. Chem. 2015, 58, 9395-9413.
A newly identified berberine derivative induces cancer cell senescence by stabilizing endogenous G-quadruplexes and sparking a DNA damage response at the telomere region, Oncotarget 2015, 6, 35625-35635. ?
Chemical intervention of the NM23-H2 transcriptional programme on c-MYC via a novel small molecule, Nucleic Acids Res. 2015, 43, 6677-6691. ?
Discovery of small molecules for up-regulating the translation of antiamyloidogenic secretase, a disintegrin and metalloproteinase 10 (ADAM10), by binding to the G-quadruplex-forming sequence in the 5′ untranslated region (UTR) of Its mRNA, J. Med. Chem. 2015, 58, 3875-91.?
Identification of selective G-quadruplex DNA binder by a multistep virtual screening approach, Chem. Commun. 2015, 51, 198-201.
Discovery of a new fluorescent light-up probe specific to parallel G-quadruplexes, Chem. Commun. 2014, 50, 12173 - 12176. ?
Development of a new colorimetric and red-emitting fluorescent dual probe for G-quadruplex nucleic acids, Chem. Commun. 2014, 50, 6927 - 6930.?
Rutaecarpine analogues reduce lipid accumulation in adipocytes via inhibiting adipogenesis/lipogenesis with AMPK activation and UPR suppression, ACS Chem. Biol. 2013, 8, 2301-2311.
Development of a universal colorimetric indicator for G-quadruplex structures by the fusion of thiazole orange and isaindigotone skeleton, Anal. Chem. 2012, 84, 6288–6292.
Inhibition of cell proliferation by quindoline derivative (SYUIQ-05) through its preferential interaction with c-myc promoter G-quadruplex, J. Med. Chem. 2011, 54, 5671-5679.
Effective detection and separation method for G-quadruplex DNA based on its specific precipitation with Mg²⁺, Biomacromolecules 2010, 11, 3384-3389.
Turning off transcription of the bcl-2 gene by stabilizing the bcl-2 promoter Quadruplex with Quindoline Derivatives, J. Med. Chem. 2010, 53, 4390-4398.
Isaindigotone derivatives: A new class of highly selective ligands for telomeric G-quadruplex DNA, J. Med. Chem. 2009, 52, 2825-2835.
5-N-Methylated quindoline derivatives as telomeric G-quadruplex stabilizing ligands: effects of 5-N positive charge on quadruplex binding affinity and cell proliferation, J. Med. Chem. 2008, 51, 6381-6392.
Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives, J. Med. Chem. 2007, 50, 1465-1474.
Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines, Oncogene 2006, 25, 503-511.
Synthesis and evaluation of quindoline derivatives as G-quadruplex inducing and stabilizing ligands and potential inhibitors of telomerase, J. Med. Chem. 2005, 48, 7315-7321.